---
layout: default
title: Ropeginterferon Alfa-2B
parent: 僅模型預測 (L5)
nav_order: 314
evidence_level: L5
indication_count: 10
---

# Ropeginterferon Alfa-2B
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropeginterferon Alfa-2b: Original Indication Not on Record → Laubry-Pezzi Syndrome (Low-Confidence Prediction)

## One-Sentence Summary

> The original approved indication for ropeginterferon alfa-2b is not available in this evidence pack (`original_indications` is empty; MOA marked as data gap).
> The TxGNN model's top-ranked prediction is **Laubry-Pezzi syndrome** (a congenital heart defect), with a score of **99.93%** but
> **zero supporting clinical trials and zero literature**. The evidence pack itself flags this as a likely false positive from embedding-space overfitting rather than a genuine repurposing signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (data gap — `original_indications` is empty) |
| Predicted New Indication | Laubry-Pezzi syndrome |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Norway Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for ropeginterferon alfa-2b (marked `[Data Gap]` in this evidence pack). No original indication is on record either, which prevents any assessment of mechanistic continuity between an established use and the predicted new indication.

More importantly, the model's own rationale field for this top prediction states explicitly that Laubry-Pezzi syndrome — a congenital cardiac malformation (ventricular septal defect with overriding aorta) — has **no known mechanistic relationship** to interferon's immunomodulatory, antiviral, or antiproliferative activity, and that the extremely high TxGNN score combined with zero clinical or literature evidence is a "typical false-positive pattern from embedding-space overfitting." The same pattern (very high score, zero evidence, no plausible mechanism) repeats across ranks 1–5 and 7–10, all of which are structural/congenital or chromosomal disorders unrelated to interferon pharmacology.

**⚠️ Notable data quality anomaly at rank 6:** The candidate "disorder of fucoglycosan synthesis" is the only entry in the top 10 with attached literature (4 papers, L2 evidence) — but all 4 papers are about **polycythemia vera (PV)** and ropeginterferon alfa-2b's established JAK2V617F-suppressing, interferon-α-mediated mechanism, not about the labeled rare metabolic disease. This strongly suggests a disease-ontology labeling error in the underlying knowledge graph rather than a genuine link to fucoglycosan metabolism. It is worth noting for context that ropeginterferon alfa-2b (Besremi) is an interferon already used clinically for PV in other markets — this is not a novel prediction so much as a mislabeled instance of an existing, well-established indication.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

*(Note: the top-ranked candidate, Laubry-Pezzi syndrome, has no attached literature. The only literature in this evidence pack is attached to rank 6, "disorder of fucoglycosan synthesis," and concerns polycythemia vera rather than the labeled disease — see data quality note above.)*

---

## Norway Market Information

No marketing authorizations are currently on record for this drug (`total_licenses: 0`).

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data are all marked as data gaps in this evidence pack; DDI query status is "not found.")*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Every prediction in this batch is L5 (model score only, no clinical trials, no literature) except rank 6, whose only literature does not actually correspond to its labeled disease. The top-ranked candidate is explicitly flagged in its own rationale as a probable false positive. There is no basis to advance this candidate to safety or clinical review.

**To proceed, the following is needed:**
- TFDA/EMA package insert data (warnings, contraindications) — currently a **blocking** data gap (DG001)
- MOA data via DrugBank API — currently a **high-severity** data gap (DG002)
- Confirmation of the drug's actual original approved indication(s), since `original_indications` is empty
- Correction of the disease-ontology mapping for rank 6 ("disorder of fucoglycosan synthesis" vs. its attached polycythemia vera literature) — this may reveal a real, already-established indication worth tracking separately rather than treating as a novel repurposing candidate
- Re-run or re-validate the TxGNN prediction batch for this drug once the ontology mapping issue is resolved, as the current top-10 list does not appear to reflect real signal
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

